First Author: R.Rubinfeld USA
Co Author(s): W. Trattler G. Perez M. Adi N. Martin G. Lacayo P. Majmudar
Purpose:
To evaluate the efficacy of CXL in patients with varying grades of ectatic corneal disease.
Setting:
Center for Excellence in Eye Care, Miami, Fl
Methods:
Patients that received epithelial-on CXL were evaluated and classified into mild, moderate, or severe keratoconus based on pre-Op steep K values. Patients with a steep K less than 50 D were considered to have mild keratoconus, patients with a pre-Op steep K between 50.1D and 55 D were considered to have moderate keratoconus, and patients with a pre-Op steep K greater than 55.1D were considered to have severe keratoconus. Evaluated patients had a pre-op diagnosis of keratoconus, pellucid marginal degeneration (PMD), post-LASIK ectasia, or post-PRK ectasia. A minimum of 3 months follow-up was required and patients with corneal opacities and/or complications were excluded. Outcome measures included UCVA, BSCVA, astigmatism, steep K, and spherical equivalent.
Results:
149 eyes met inclusion criteria. 80 of these eyes were classified as mild, 42 eyes were classified as moderate, and 27 eyes were classified as severe. In the mild, moderate, and severe groups 73%, 67%, and 70% of eyes were males, respectively. Each group had a minimum of 3 months follow-up. 68%, 79%, and 100% of eyes in mild, moderate, and severe groups were diagnosed with keratoconus pre-Op. 3% and 5% of eyes in mild and moderate groups, respectively, were diagnosed with PMD pre-Op. 23% and 14% of eyes in mild and moderate groups, respectively, were diagnosed with post-LASIK ectasia pre-Op. 5% of mild keratoconic eyes were diagnosed with post-PRK ectasia pre-Op. 51% of mild eyes, 45% of moderate eyes, and 31% of severe eyes experienced improvement in UCVA. 48% of mild eyes, 60% of moderate eyes, and 37% of severe eyes experienced improvement in BSCVA. 26% of mild eyes, 51% of moderate eyes, and 45% of severe eyes experienced 1D or more reduction in steep K. 20% of mild eyes, 20% of moderate eyes, and 31% of severe eyes experienced 1D or more reduction in spherical equivalent.
Conclusions:
Epi-On CXL is proven safe and effective for patients classified as having mild, moderate, or severe corneal ectatic diseases. FINANCIAL DISCLOSURE?: ... has significant investment interest in a company producing, developing or supplying product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented
Please wait while information is loading.
